# Johnson & Johnson (JNJ) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/JNJ
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Jul 15, 2026

Johnson & Johnson (JNJ) last closed at $257.77, near the top of its 52-week range of $154.80–$269.43. Composite market sentiment across 1 analysis is positive (+34 on a −100 to +100 scale), as of Jul 15, 2026.

## What the data says

At its most recent close of $257.77, Johnson & Johnson is trading near the upper end of its 52-week range, which runs from a low of $154.80 to a high of $269.43. The stock now sits close to that high, and the width of the range shows shares have climbed a long way from their weakest point over the past year rather than drifting within a narrow band.

The market is valuing the business at roughly $611 billion. Its trailing price-to-earnings ratio of about 29.9 steps down to a forward figure near 19.9, reflecting expected earnings ahead of the current trailing base, while the price-to-book ratio sits above 7. Underneath those multiples, the company converts close to 22 percent of revenue into profit and has grown revenue by about 10 percent, and it pays a dividend yielding around 2.1 percent. A beta of roughly 0.24 indicates the shares have historically moved far less than the broader market, tending to stay steadier when the market swings.

Recent news flow has centered less on the company itself than on the sectors and investment vehicles around it. Several items track healthcare and pharmaceutical themes at large — projected growth in oncology and AI-assisted orthopedic surgery markets, and comparisons of health-care and drug-focused ETFs — while others frame the stock through its dividend profile, including coverage of a large investor increasing a stake and pieces on dividend-paying equities. Together, the headlines lean toward the wider industry backdrop and income characteristics rather than a single company-specific development.

## About Johnson & Johnson

Johnson & Johnson researches, develops, manufactures, and sells healthcare products worldwide. The company organizes its work into two segments. Its Innovative Medicine segment offers prescription pharmaceuticals across therapeutic areas including oncology, immunology, neuroscience, infectious diseases, pulmonary hypertension, and cardiovascular and metabolic disease, reaching patients through wholesalers, distributors, hospitals, and healthcare professionals.

Its MedTech segment supplies medical devices and technologies used in surgery, orthopedics, cardiovascular care, and vision. These include products for joint reconstruction, trauma, spine, and sports injuries; instruments and systems for open, laparoscopic, and robotic surgery, such as energy devices, stapling, wound closure, and biosurgery; and vision care products, including ACUVUE contact lenses and TECNIS intraocular lenses for cataract surgery. Founded in 1886, Johnson & Johnson is headquartered in New Brunswick, New Jersey.

## Company profile

- Symbol: JNJ
- Exchange: NYSE
- Security type: Stock
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Composite sentiment: positive (34 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $611.07B |
| Enterprise value | $644.01B |
| Trailing P/E | 29.86 |
| Forward P/E | 19.9 |
| Price to book | 7.52 |
| Price to sales | 6.34 |
| Dividend yield | 2.08% |
| Beta | 0.24 |
| Net margin | 21.83% |
| Revenue growth | 9.90% |
| Earnings growth | -52.90% |
| 52-week high | $269.43 |
| 52-week low | $154.80 |
| Average volume | 8.1M |

## Related stocks

- [LLY](https://synoptiv.com/stock/LLY)
- [MRK](https://synoptiv.com/stock/MRK)
- [PFE](https://synoptiv.com/stock/PFE)
- [BMY](https://synoptiv.com/stock/BMY)
- [ZTS](https://synoptiv.com/stock/ZTS)
- [RPRX](https://synoptiv.com/stock/RPRX)
- [VTRS](https://synoptiv.com/stock/VTRS)
- [ELAN](https://synoptiv.com/stock/ELAN)
- [AXSM](https://synoptiv.com/stock/AXSM)

## Recent news

- [Dow Jones Futures Rise; Goldman, CrowdStrike Jump, But AI Stocks Need To Do This](https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-goldman-crowdstrike-ai-stocks-asml-morgan-stanley/?src=A00220&yptr=yahoo) — Jul 14, 2026
- [Earnings, Warsh Testimony: What to Watch the Rest of the Week](https://www.wsj.com/finance/live/stock-market-today-dow-sp-500-nasdaq-07-15-2026-2a3dd235/card/earnings-warsh-testimony-what-to-watch-the-rest-of-the-week-dcb9fdde?siteid=yhoof2&yptr=yahoo) — Jul 14, 2026
- [Dow Jones Futures: Goldman, CrowdStrike Jump, AI Stocks Need To Do This; ASML, Morgan Stanley Due](https://finance.yahoo.com/m/ff2fea6d-f6fc-389f-b0c6-62b745afe36d/dow-jones-futures%3A-goldman%2C.html) — Jul 14, 2026
- [Top dow jones movers in Tuesday's session](https://www.chartmill.com/news/SHW/Chartmill-50969-Top-dow-jones-movers-in-Tuesdays-session) — Jul 14, 2026
- [The Paid-To-Hold Play On ISRG Stock: A 12% Income](https://www.trefis.com/articles/607075/the-paid-to-hold-play-on-isrg-stock-a-12-income/2026-07-14) — Jul 14, 2026
- [What Lilly's Peer-Beating Numbers Cost You](https://www.trefis.com/articles/607068/what-lillys-peer-beating-numbers-cost-you/2026-07-14) — Jul 14, 2026
- [A Fresh Look At Syndax Pharmaceuticals](https://seekingalpha.com/article/4922057-a-fresh-look-at-syndax-pharmaceuticals) — Jul 14, 2026
- [This Healthcare Giant Still Checks Every Box for Long-Term Investors](https://247wallst.com/investing/2026/07/14/this-healthcare-giant-still-checks-every-box-for-long-term-investors/) — Jul 14, 2026
- [ASML Could Swing 7.5% After Earnings on Wednesday](https://www.benzinga.com/markets/options/26/07/60457437/asml-could-swing-7-5-after-earnings-on-wednesday) — Jul 14, 2026
- [A $1.4 Million Portfolio That Delivers Reliable Income Through Bull and Bear Markets](https://247wallst.com/personal-finance/2026/07/14/a-1-4-million-portfolio-that-delivers-reliable-income-through-bull-and-bear-markets/) — Jul 14, 2026

## Frequently asked questions

### What is the current market sentiment for JNJ?

As of Jul 15, 2026, Johnson & Johnson (JNJ) carries positive (+34 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has JNJ stock been performing?

Johnson & Johnson last closed at $257.77, near the top of its 52-week range of $154.80–$269.43.

### What is JNJ's market cap and valuation?

Johnson & Johnson has a market capitalization of about $611.07B, a trailing P/E of 29.9, a dividend yield of 2.08%.

### What sector is JNJ in, and who are its competitors?

Johnson & Johnson operates in the Healthcare sector, specifically Drug Manufacturers - General. Comparable companies include LLY, MRK, PFE, BMY, ZTS.

### Where can I find a full analysis of JNJ?

The full JNJ report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/JNJ/v/1) (account and access required)